Use of biomimetic three-dimensional technology in cardiac regeneration after myocardial infarction: the effect of acellular devices on cardiac ventricular function and remodeling

• Grant number: 17/01508-9
• Support Opportunities: Scholarships abroad - Research
• Start date: August 16, 2017
• End date: August 15, 2018
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: Lindemberg da Mota Silveira Filho
• Grantee: Lindemberg da Mota Silveira Filho
• Host Investigator: William Richard Wagner
• Host Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• Institution abroad: University of Pittsburgh (Pitt), United States

Abstract

Ischemic and non-ischemic miocardiopathy remains a lethal condition nowadays. Despite early percutaneous or medical revascularization after an acute myocardial infarct, many patients still develop ventricular dilation and severe heart failure due to cardiac remodeling. Possibility of regenerating myocardium already damaged or at least inducing a more positive cardiac remodeling with use of biodegradable scaffolds have been attempted in many experimental studies. There have been questionings on best time of material application, on which sort of material would enhance more recovery and whether use of scaffolds may help remodeling chronic ischemic hearts.The aims of this study are to verify if application of different kinds of biodegradable scaffolds may improve hemodynamic parameters, reduce fibrosis and induce better heart remodeling in a chronic ischemia animal model. Left ventricle infarct will be created by ligation of Left Anterior Descending artery of Wistar rats. Infarct area will be confirmed by echocardiography. After 4 weeks,animals will be operated and divided into one of the following groups: Control, injection of biodegradable hydrogel or application of hydrogel patch on infarct area. After 6 weeks, animals will be analyzed by echocardiography and sacrificed. Area of fibrosis and ventricular width will be quantified. Samples of ventricle will be collected to measure inflammatory markers such as TNF and interleukins. It is expected that animals who receive scaffolds will show better ecocardiographic parameters, less fibrosis, better infarct area width and better remodeling. It is questionable if any form of employed scaffold will be associated to better results. TNF and interleukins will probably vary between treated animals and control.These results, if confirmed, may favor the use of such materials in patients, either in surgically or in more conservative treatment scenarios. (AU)